| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London | 358 | GlobeNewswire (Europe) | LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.11. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.11. | OKYO Pharma to Present at the Stifel 2026 Healthcare Conference | 337 | GlobeNewswire (Europe) | LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 06.10. | OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain | 393 | GlobeNewswire (Europe) | NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal painFirst patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN
LONDON and NEW YORK... ► Artikel lesen | |
| 06.10. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.09. | OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences | 379 | GlobeNewswire (Europe) | OKYO demonstrates continued commitment to optometry and ophthalmology
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 29.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 09.09. | OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 | 430 | GlobeNewswire (Europe) | Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09,... ► Artikel lesen | |
| 08.09. | OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference | 435 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 08.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.07. | OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer | 324 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 | 417 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Director | 395 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.07. | OKYO Pharma CEO purchases 15,000 shares at $1.54 each | 2 | Investing.com | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Chief Executive Officer | 380 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 370 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma executive purchases 3,500 shares at $1.40 each | 2 | Investing.com | ||
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | 385 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Medical Officer | 377 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,411 | -1,23 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| NOVAVAX | 7,180 | -0,97 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| PALATIN TECHNOLOGIES | 5,150 | 0,00 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| OCUGEN | 0,668 | -0,89 % | Ocugen: Lizenzdeal mit Celairis - OCU400 bekommt Asien-Pazifik-Schub | ||
| VIVORYON THERAPEUTICS | 0,678 | +0,59 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,289 | +2,12 % | 14 Tage oder 60 Monate Lagerung: Warum Gilead, Mesoblast und NurExone regenerative Therapien unterschiedlich verfügbar machen | ||
| SAREPTA THERAPEUTICS | 13,260 | 0,00 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| IDEXX LABORATORIES | 624,00 | -1,95 % | ROUNDUP: IDEXX Laboratories Boost FY26 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Monday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) raised its earnings and revenue guidance for... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,800 | +7,63 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| REDHILL BIOPHARMA | 0,350 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| MYRIAD GENETICS | 5,100 | +1,15 % | Myriad Genetics auf Stephens-Konferenz: Verstärkter Fokus auf Onkologie | ||
| MANNKIND | 3,687 | 0,00 % | MannKind auf der Jefferies Global Healthcare Conference: Wachstumstreiber formieren sich - Profitabilität für Q4 2026 im Visier | ||
| ONCO-INNOVATIONS | 0,120 | +6,37 % | Onco-Innovations Limited: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| NOVOCURE | 9,782 | +0,20 % | JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer | Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields)... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,550 | +1,83 % | Ocular Therapeutix auf der UBS Global Biopharma Conference 2026: US-Zulassungsantrag für AXPAXLI rückt näher |